Abstract: The invention relates to compounds of Formula I: or pharmaceutically acceptable solvates thereof, as well as their use in the treatment and/or prevention of diseases or conditions associated with a dysfunction of CFTR channel activity, in particular cystic fibrosis.

Abstract: The present invention concerns compounds belonging to the family of fluorinated pyridazin-3-ones, for the use thereof in the treatment of broncho-pulmonary conditions. In compounds having a formula, or a pharmaceutically acceptable salt of the compound, the formula includes R1 representing H, an alkyl, an aryl or a heteroaryl; either E2 and E3 representing, separately from each other, H, an alkyl, an aryl or a heteroaryl, or R2 and R3 being bridged within a same cycle or via several cycles; and F representing CF3, (CF2)nCF3 or CF2H, with n representing an integer of between 1 and 7.